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Abstract 1 
Objectives: To establish whether children with relapsing acquired demyelinating syndromes (RDS) and 2 
myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) show distinctive clinical and radiological 3 
features and generate a diagnostic algorithm for the main RDS for clinical use.  4 
 5 
Methods: A panel reviewed the clinical characteristics, MOG-Ab and aquaporin-4 (AQP4) Ab, 6 
intrathecal oligoclonal bands and Epstein-Barr virus serology results of 110 children with RDS. A 7 
neuroradiologist, blinded to the diagnosis, scored the MRI scans. Clinical, radiological, and serological 8 
tests results were compared. 9 
 10 
Results: 56.4% of children were diagnosed with multiple sclerosis (MS), 25.4% with neuromyelitis 11 
optica spectrum disorder (NMOSD), 12.7% with multiphasic disseminated encephalomyelitis (MDEM), 12 
and 5.5% with relapsing optic neuritis (RON). Blinded analysis defined baseline MRI as typical of MS in 13 
93.5% of MS children. ADEM presentation was only seen in the non-MS group. 30.7% of NMOSD 14 
cases were AQP4-Ab positive. MOG-Ab were found in 83.3% of AQP4-Ab negative NMOSD, 100% 15 
MDEM, and 33.3% with RON. Children with MOG-Ab were younger, less likely to present with area 16 
postrema syndrome, had lower disability, longer time to relapse, and more cerebellar peduncle lesions 17 
than AQP4-Ab NMOSD. A diagnostic algorithm, applicable to any episode of CNS demyelination, leads 18 
to four main phenotypes: MS, APQ4-Ab NMOSD, MOG-Ab-associated disease, and antibody-negative 19 
RDS. 20 
 21 
Conclusion: Children with MS and AQP4-Ab NMOSD showed features typical of adult cases. Since 22 
MOG-Ab positive children showed notable and distinctive clinical and MRI features, they were grouped 23 
into a unified phenotype (MOG-Ab-associated disease), included in a new diagnostic algorithm. 24 
  25 
  4 
Introduction 1 
Paediatric relapsing acquired demyelinating syndromes (RDS)1 of the central nervous system (CNS) 2 
define a group of diseases with different phenotypes.  3 
 4 
The most common pediatric RDS is multiple sclerosis (MS). The 2010 McDonald criteria enable a 5 
diagnosis of MS in children over the age of 11 years, presenting with a clinically isolated syndrome 6 
(CIS) and MRI evidence of dissemination in space (DIS) and time (DIT)2, providing that the clinical 7 
presentation does not resemble ADEM3, 4. Although a proportion of children present with MS before the 8 
age of 12 years, the 2010 McDonald criteria2 show a low positive predictive value5 in this patient group.    9 
 10 
Another RDS is NMOSD, which is stratified according to the presence/absence of AQP4-Ab6. About 11 
30% of AQP4 seronegative NMOSD adult patients have myelin oligodendrocyte glycoprotein antibodies 12 
(MOG-Ab)7. Comparative studies between MOG-Ab and AQP4-Ab positive NMOSD in adults8-10 and 13 
children11 have shown that MOG-Ab positive patients are younger, more frequently male, and have a 14 
better outcome and more often a monophasic course. 15 
 16 
In addition to AQP4-Ab seronegative NMOSD12, MOG-Ab have been detected in other RDS, such as 17 
multiphasic disseminated encephalomyelitis (MDEM)13, recurrent optic neuritis (RON)14, and acute 18 
disseminated encephalomyelitis, followed by recurrent or monophasic optic neuritis (ADEM-ON)15. 19 
 20 
We evaluated retrospectively a large cohort of children with RDS who underwent clinical assessments, 21 
MRI, oligoclonal bands (OCBs) testing in the cerebrospinal fluid, AQP4-Ab, MOG-Ab, and Epstein-Barr 22 
virus (EBV) antibody testing in the serum, as part of routine clinical protocols. We aimed to identify the 23 
key features of RDS that unify phenotypes, and additionally focused on patients with MOG-Ab, to 24 
investigate whether they show distinct clinical and radiological features, independently of their original 25 
diagnosis. Our ultimate goal was to develop a diagnostic algorithm that provides advice on how to reach 26 
the diagnosis of the newly defined phenotypes, by suggesting sequential diagnostic tests and 27 
supporting features.  28 
  29 
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Methods  1 
Participants 2 
A total of 110 children with RDS were retrospectively studied. Consecutive children attending follow-up 3 
visits between September 2014-September 2015 were identified from three UK & Ireland Childhood 4 
CNS Inflammatory Demyelination Working Group (UK-CID) centers: Great Ormond Street Hospital, 5 
Evelina London Children Hospital, and Birmingham Children Hospital. The diagnosis of RDS was 6 
defined as two or more episodes of acquired CNS demyelination lasting > 24 hours involving the optic 7 
nerve, brain or spinal cord, associated with T2 lesions on MRI. Patients with monophasic ADEM and 8 
CIS (even if meeting McDonald criteria after first event) were not included.  9 
 10 
Standard Protocol Approvals, Registrations, and Patient Consents 11 
This study was approved by Great Ormond Street Hospital Research and Development Department 12 
(reference: 16NC10).  13 
 14 
Procedure  15 
All clinical records were reviewed by one YH, who summarized patients’ demographics, clinical 16 
presentations, demyelinating phenotypes at visits, timing and features at relapses, and expanded 17 
disability status scale (EDSS) at 2 years from onset. Onset demyelinating phenotype was determined 18 
based on the clinical features and neurological examination according to established criteria3 (without 19 
neuroimaging reference) as being optic neuritis (ON), transverse myelitis (TM), neurological deficits 20 
associated with encephalopathy (ADEM) or without encephalopathy (a brainstem, cerebellar and 21 
hemispheric CIS) 22 
All patients had undergone brain and spinal cord imaging according to local MRI protocols (not routinely 23 
including orbits). Gadolinium enhanced imaging was performed in all cases, but not always at the first 24 
scan. 25 
Within 1 month of an acute event (either onset or relapse), clinically symptomatic children underwent 26 
testing for serum AQP4-Ab and MOG-Ab (not CSF), as part of routine assessments of children with 27 
demyelinating diseases, performed at the Clinical Neuroimmunology service at the Oxford Radcliffe 28 
Hospital Trust, using live cell-based assays16, 17(This laboratory receives samples for antibody testing 29 
from all over the world including the US where MOG-Ab testing is not available).  Qualitative analyses of 30 
serum and CSF oligoclonal patterns were performed by isoelectric focusing on agarose gels followed by 31 
immunoblotting18, and serum IgG-Ab directed against Epstein-Barr virus capsid antigens, nuclear 32 
antigens (EBNA1), and early antigens were measured using standard ELISA kits, locally.  33 
 34 
Clinical review panel  35 
  6 
At least two clinicians who were not involved with the direct clinical care of the children and two 1 
pediatric neuroradiologists reviewed the case summaries and all neuroimaging, assigned the cases to 2 
one of the following diagnostic categories: 3 
1. MS, fulfilling the 2013 International Pediatric Multiple Sclerosis Study Group (IPMSSG) 4 
consensus criteria3 and the 2010 McDonald criteria2 5 
2. NMOSD, fulfilling the 2015 Wingerchuk criteria6  6 
3. MDEM and ADEM-ON, fulfilling the 2013 IPMSSG consensus criteria3  7 
4. Recurrent demyelination in a single CNS area without evidence of clinically-silent disease 8 
(e.g., RON) 9 
 10 
Blinded radiological analysis  11 
A third neuroradiologist (FB) performed a separate analysis to assess whether imaging characteristics 12 
alone can support the diagnosis of a specific syndrome, being blind to the clinical features and the 13 
antibody results. The following analysis was repeated separately for baseline MRI and follow-up scans. 14 
Lesion morphology, distribution, and location were used to support a diagnosis of MS. MS plaques are 15 
ovid and perpendicularly oriented to the ventricular surface, they occur bilaterally, but are typically 16 
asymmetrical, and are distributed in both the supra- and infratentorial compartments. Although MS 17 
lesions can be located anywhere in the CNS, they frequently seen in the juxtacortical, periventricular, 18 
and infratentorial regions19. MRI scans were grouped into the following categories; (1) not MS, (2) not 19 
typical of MS, (3) some MS features, (4) typical of MS. 20 
 21 
For categories 1 and 2, one of the following five main imaging patterns, which included features known 22 
to be associated with NMOSD6, 20 and features recently reported in patients with MOG-Ab13, 21 was 23 
chosen by the neuroradiologist as the predominant pattern: (i) disease localized to brainstem and 24 
hypothalamus; (ii) predominantly confluent, hazy/poorly marginated lesions involving both grey matter 25 
and white matter; (iii) extensive confluent ‘leukodystrophy-like’ MRI pattern; (iv) sharply demarcated 26 
hemispheric white matter lesions (>3cm); (v) TM and/or ON with normal intracranial appearance or non-27 
specific white matter lesions. Additionally, for the follow-up scans, the two following imaging features 28 
were looked for: (i) almost or complete resolution of lesions, (ii) destructive lesions, defined as severe 29 
rarefaction of tissue leading to central low signal on FLAIR with associated volumes loss.  30 
Finally, the presence of lesions in the diencephalon, dorsal brainstem, periependymal area surrounding 31 
the lateral ventricles, longitudinally extensive TM (LETM), cortical grey matter, thalamus, basal ganglia, 32 
juxtacortical and deep white mater involvement more than periventricular, cerebellar peduncles, pons 33 
and optic nerves/tracts, considered to be typical of patients with NMOSD with AQP4-Ab (according to 34 
Wingerchuk criteria)6, 20 and MOG-Ab associated demyelination, were recorded.  35 
 36 
Statistical analysis  37 
  7 
To compare the demographic, clinical, radiological and serological characteristics between the 1 
phenotypes, parametric or non-parametric statistical tests (Mann–Whitney U and Kruskal Wallis tests) 2 
were used for continuous distributions, as appropriate given normality, and χ2 or Fisher’s exact tests for 3 
nominal data.  Results associated with a p-value <0.05 were considered significant. Data were analyzed 4 
using GraphPad Prism 5. 5 
 6 
Results  7 
110 consecutive children with RDS were studied. The median length of follow-up (from first clinical 8 
presentation) was 4 years (IQR3-7). During this period, a median of 4 repeated MRI scans were 9 
performed (range 3-10). All patients had brain MRI at onset and 95/110 (86.3%) had spinal cord MRI 10 
too.  11 
The panel diagnosed 62/110 (56.4%) children with MS, 28/110 (25.4%) with NMOSD, 14/110 (12.7%) 12 
with MDEM, and 6/110 (5.5%) with RON (not fulfilling criteria for chronic relapsing inflammatory optic 13 
neuropathy22). 14 
Patients’ demographic, clinical and paraclinical features and clinical disability at 2 year follow-up 15 
according to each RDS phenotype, are summarized in Table 1.  16 
 17 
Patients with MS  18 
At onset, 75.8% of MS patients presented with a brainstem, cerebellar and hemispheric CIS and 98.4% 19 
with abnormal MRI, with T2 hyperintense lesions. The majority of MS patients (94.6%) showed OCBs in 20 
the CSF and all patients showed EBV IgG. (Table 1). No differences in the clinical, radiological and 21 
immunological features between MS children younger (32.3%) and older than 11 years (67.7%) at onset 22 
were detected (Supplemental Table 1).  23 
 24 
Comparison between children with MS and non-MS RDS  25 
48/ 110 (43.6%) children did not have MS; the majority of these patients had NMOSD (28/48, 58.3%), 26 
followed by MDEM (14/48, 29.2%), and RON (6/48, 12.5%)(Table 1, Supplemental Figure 1).  MS 27 
patients were older and more likely to present with a brainstem, cerebellar and hemispheric CIS than 28 
non-MS RDS; ADEM presentation was only seen in the non-MS group (all p values <0.0001). Brain MRI 29 
abnormalities at presentation were more frequently seen in the MS than non-MS RDS (p<0.0001). 30 
MOG- and AQP4-Abs were found exclusively in the non-MS group (p<0.0001). All MS patients tested 31 
had evidence of remote EBV infection compared to 42.9% of non-MS patients and more frequently 32 
showed intrathecal synthesis of OCBs (all p values <0.0001) (Table 1).  33 
 34 
The blinded analysis of baseline MRI scans, done in all 110 patients, correctly identified 58/62 (93.6%; 35 
52 category 4; 6 category 3) children with MS and all 48 children with non-MS (100%; 38 category 1; 10 36 
category 2). Follow-up MRI scans analysis only identified an additional 2 MS cases  (The MRI scans of 37 
  8 
the 4 MS patients with atypical imaging are shown in Supplemental Figure 2). All 45 patients with 1 
spinal cord lesions had short segment myelitis by contrast to 12/13 patients in the non-MS group who 2 
had LETM (p<0.0001). 3 
 4 
Autoantibodies in children with RDS  5 
Thirty-four out of 41 (82.9%) patients with non-MS RDS (who were tested) were positive to either 6 
AQP4-Ab or MOG-Ab. In particular, 30.7% (8/26) of NMOSD cases tested were AQP4-Ab-positive. 7 
83.3% (15/18) of AQP4-Ab negative NMOSD cases were MOG-Ab-positive. No patients had antibodies 8 
to both antigens. MOG-Ab were found in 100% (9/9) of MDEM tested cases and 33.3% (2/6) of RON 9 
tested cases. Seven patients were negative to both antibodies: 4 relapsed with RON and 3 with 10 
NMOSD.  11 
Clinical characteristics of patients with AQP4-Ab NMOSD and all patients with MOG-Ab associated 12 
disease are detailed in Table 2. 13 
 14 
Comparison between MOG-Ab-positive and AQP4-Ab-positive children 15 
Children with MOG-Ab grouped together (independently of their original RDS diagnosis) were younger 16 
(p=0.048), less likely to present with area postrema syndrome (p=0.0067), more likely to present with 17 
ADEM (p=0.034), had lower disability at 2-year follow-up (p=0.03) and a longer time to relapse 18 
(p=0.016) than NMOSD with AQP4-Ab (Table 2 and Supplemental Figure 3).  19 
 20 
When the MRI patterns and lesion locations between MOG-Ab-and AQP4-Ab-positive patients were 21 
compared, patients with AQP4-Ab were more likely to have disease restricted to the brainstem and/or 22 
hypothalamus (at onset 38% vs 0%, p=0.0094, and at follow-up 50% vs 0%, p=0.0015). Destructive 23 
lesions at follow-up scans were seen in the majority of AQP4-Ab-positive patients (62.5%) and in none 24 
of the MOG-positive patients (p=0.002) (Table 3, Supplemental Figure 4). Lesions located in dorsal 25 
brainstem were more frequently seen in AQP4-Ab-positive patients (87.5% vs 11.5%, p=0.0085), whilst 26 
lesions in the cerebellar peduncles were only seen in the MOG-positive patients at onset and follow-up 27 
(p=0.03 and p=0.011) (Table 3, Figure 1). Finally, leukodystrophy-like lesions were only seen in MOG-28 
Ab-positive patients (Table 3, Figure 1). 29 
 30 
Diagnostic algorithm  31 
We propose a diagnostic algorithm (Figure 2), applicable to any episode of CNS demyelination, which 32 
leads to four main demyelinating syndromes: MS, APQ4-Ab NMOSD, MOG-Ab associated disease and 33 
Ab-negative RDS. 34 
 35 
  9 
The first recommended diagnostic test is brain and spinal cord MRI. If the clinical features of a CNS 1 
attack and MRI findings are considered to be typical/suggestive of MS, then the McDonald diagnostic 2 
criteria should be applied.  3 
 4 
In children whose MRI is not typical/suggestive of MS, but have clinical and radiological features 5 
suggestive of NMOSD, AQP4-Ab testing is recommended, particularly in children having an area 6 
postrema syndrome, MRI abnormalities localized to the brainstem and hypothalamus, and destructive 7 
lesions. MOG-Ab should be tested in AQP4-Ab negative cases.   8 
 9 
In children whose MRI is not typical of MS or NMOSD, but the clinical and radiological presentation 10 
resembles ADEM, MOG-Ab testing is recommended. Additionally, MOG-Ab testing is recommended in 11 
children who with poorly marginated lesions in the cerebellar peduncle, and in children with a 12 
“leukodystrophy-like” MRI pattern.     13 
 14 
Consideration of alternative diagnoses (e.g. inflammatory, infectious and neurometabolic) and then 15 
monitoring are recommended in the remaining minority of Ab-negative RDS. 16 
  17 
  10 
 1 
Discussion  2 
Based on the observations in this large cohort of 110 children with RDS, a diagnostic algorithm 3 
applicable to any episode of CNS demyelination in children was developed to reach the diagnosis of 4 
four main phenotypes: MS, AQP4-Ab NMOSD, MOG-Ab associated disease and seronegative RDS 5 
children. 6 
 7 
Brain and spinal cord MRI is the first diagnostic test to be performed. This helps to reach the diagnosis 8 
of MS, which is the most common RDS in our cohort (56.4%), even if the MRI is blindly analysed in 9 
isolation. The lack of clinical, radiological and immunological differences between MS children younger 10 
and older than 11 years suggests that the 2010 McDonald diagnostic criteria for MS2 can be applied to 11 
children of any age. Current guidance3 for the diagnosis of MS in children recommends caution for 12 
children younger than 12 years, but our study indicates that if clinical and MRI features typical of adult 13 
MS are seen in children, there should be confidence about the diagnosis of MS.  14 
 15 
None of the children with MS presented with ADEM. Previous studies have shown that 5-29%23, 24 of 16 
children initially diagnosed with ADEM have further demyelinating events that are atypical for ADEM, 17 
but leads to a diagnosis of MS. However, MOG-Ab were not tested in these patients. These previous 18 
studies have reported that MS in children showed unique MRI features, such as oedema and 19 
widespread white-matter involvement, increased frequency of LETM, and lower frequencies of 20 
intrathecal oligoclonal band positivity than adults with MS1, 23, whilst these features were absent in our 21 
MS patients, but typical of MOG-Ab associated disease.  22 
 23 
AQP4-Ab testing should be performed in patients with clinical and/or radiological features suggestive of 24 
NMOSD6. We found that two third of non-MS children had NMOSD, of which 30.7% tested were AQP4-25 
Ab-positive, which is lower than previously reported in adult8, 21, 25 and pediatric cohorts26. This is in 26 
keeping with previous studies of AQP4-Ab seropositivity exponentially increasing with age, particularly 27 
in women27.  Nevertheless, comparison between different cohorts has to be made with caution if referral 28 
pathways are different between centers.  29 
 30 
We found that 82.9% of all patients with non-MS RDS were either AQP4-Ab or MOG-Ab positive. We 31 
detected MOG-Ab in 83.3% of NMOSD without AQP4-Ab. This was much higher than the previously 32 
reported adult cohorts7, but not surprising since MOG-Ab are known to be common in children28. 33 
Additionally, increasing recognition of this antibody and the application of the latest diagnostic criteria 34 
for NMOSD6 may also contribute to the observed high number of NMOSD patients29 and hence MOG-35 
Ab-positive cases. CSF testing for AQP4 and MOG antibodies was not performed as in both these 36 
  11 
conditions it has been shown that the antibodies originate from the periphery and serum testing is more 1 
sensitive than CSF30, 31.  2 
 3 
As we found that 100% of patients with MDEM are MOG-positive, and previous investigations detected 4 
significant association between ADEM and MOG-Ab13, 32, we feel that performing MOG-Ab testing in all 5 
patients presenting with ADEM (both monophasic and relapsing disease) is justified on the bases of 6 
expert’s opinion consensus. A key question is whether MOG-Ab negative ADEM patients show different 7 
clinical and MRI features from MOG-Ab positive ADEM patients.  Large ill-defined lesions in the 8 
cerebellar peduncle, and a leukodystrophy-like MRI pattern can be a useful clue to this diagnosis.  9 
 10 
Despite the low number of children with AQP4-Ab in this cohort we identify differences between children 11 
with AQP4-Ab vs children with MOG-Ab grouped together (independently of their original RDS 12 
diagnosis). Children with MOG-Ab were younger, less likely to present with area postrema syndrome, 13 
more likely to present with ADEM, lower disability at 2-year and a longer time to relapse than AQP4-Ab 14 
NMOSD. Therefore, we proposed to group all the MOG-Ab-positive patients into a unified phenotype 15 
(“MOG-Ab associated disease”). It is possible that the two antigenic targets (AQP4 and MOG) lead to 16 
different diseases, via different pathogenic mechanisms, which cause an autoimmune astrocytopathy in 17 
AQP4-Ab-associated disease and autoimmune oligodendrogliopathy in MOG-Ab-associated disease.33 18 
Recent studies looking at the effects of MOG-Ab in cell cultures and in mouse models showed loss of 19 
the microtubule cytoskeleton of oligodendrocytes when incubated with purified IgG from MOG-Ab 20 
positive patients,34 as well as myelin changes and altered expression of axonal proteins when injected 21 
directly into mouse brain35.  By contrast, AQP4-Ab are thought to produce astrocyte damage by 22 
complement-dependent cytotoxicity which leads to blood–brain barrier disruption causing leukocyte 23 
infiltration, and cytokine release resulting in damage to oligodendrocytes, myelin and neurons which 24 
may explain the more destructive lesions seen in this phenotype36. Abundance of AQP4 in the area 25 
postrema37 is likely to explain the increased frequency of nausea and vomiting in the AQP4-Ab positive 26 
group, together with imaging abnormalities in the dorsal brainstem and hypothalamus, as previously 27 
reported.38 28 
 29 
Overall, the very high percentage (82.9%) of children with non-MS RDS who are positive to one of the 30 
two antibodies, suggests that the majority of these children have a known antibody-mediated 31 
demyelinating disease. In the rare cases of RDS other than MS, negative to both antibodies, it is 32 
important to consider mimics of CNS demyelination. 33 
 34 
The blinded MRI analyses successfully distinguished between MS and non-MS cases already at onset. 35 
MRI abnormalities in the brainstem and hypothalamus were typical of AQP4-Ab positive patients, as 36 
previously reported,38 whilst  ill-defined lesions in the cerebellar peduncle were seen exclusively in the 37 
  12 
MOG-Ab positive patients. Future studies will aim to confirm whether this can be used as a marker for 1 
MOG-Ab associated disease. 2 
 3 
Intrathecal OCBs and the remote EBV infection confirmed previous findings39, 40, but since we did not 4 
calculate the predictive value of these tests and their role independently of MRI, we decided not to 5 
include them into the algorithm.  6 
 7 
A limitation of our study is its retrospective nature, which led to the inclusion of only relapsing cases. 8 
However, this large cohort allowed us to identify notable differences in their clinical, imaging and 9 
immunological characteristics that have led us to propose four main distinct phenotypes: MS, NMOSD 10 
with AQP4-Ab, MOG-Ab associated disease and seronegative RDS children. The distinction of MOG-11 
Ab-associated disease from the other RDS should be considered in the next revisions of the diagnostic 12 
criteria for MS and NMOSD.  13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
  24 
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Table 1. Demographics, clinical and paraclinical features of children according to their standard 1 
RDS diagnosis 2 
  All non-MS (n=48) 
 
 
 MS  
(n=62) 
NMOSD 
(n=28) 
MDEM 
(n=14) 
RON   
(n=6) 
Summary  
of all non-MS 
P Value 
MS vs 
non-MS 
Age (years) at 
presentation 
Median (IQR) 
13 (11-14) 8 (5-11) 4.5 (3-5) 10 (9.3-
12.5) 
7 (5-10) <0.0001 
Sex (M:F) 1:2.1 1:2.5 1:0.75 1:1 1:1.53 0.55 
Ethnicity  
(white: other) 
29: 33 13: 15 10: 4 5: 1 28:20 0.25 
Demyelinating phenotype at onset   
ADEM 0  
(0%) 
3 
(10.7%) 
14  
(100%) 
0  
(0%) 
17 (35.4%) <0.0001 
ON 12  
(19.4%) 
11 
(39.3%) 
0  
(0%) 
6  
(100%) 
17 (35.4%) 0.08 
TM 3  
(4.8%) 
7  
(25%) 
0  
(0%) 
0  
(0%) 
7 (14.6%) 0.51 
Brainstem, 
cerebellar and 
hemispheric CIS 
47  
(75.8%) 
8 
(28.6%) 
0  
(0%) 
0  
(0%) 
8 (16.7%) <0.0001 
Abnormal 
brain MRI at 
onset* 
61  
(98.4%) 
14  
(50%) 
14  
(100%) 
0  
(0%) 
28 (58.3%) <0.0001 
OCB 53/56 
(94.6%) 
4/25 
(16%) 
1/10 
(10%) 
0/6  
(0%) 
5/41 (12.2%) <0.0001 
EBV IgG 47/47 
(100%) 
8/12 
(66.7%) 
2/11 
(18%) 
2/5  
(40%) 
12/28 (42.9%) <0.0001 
AQP-Ab 0/56  
(0%) 
8/26 
(30.7%) 
0/9  
(0%) 
0/6  
(0%) 
8/41 (19.5%) 0.0007 
MOG-Ab 0/56  
(0%) 
15^/26 
(57.7%) 
9/9 
(100%) 
2/6  
(33.3%) 
26/41 (63.4%) <0.0001 
Time to first 
relapse 
Median months  
(IQR) 
6 
(4-12.5) 
6  
(3-16) 
18.5  
(3.8- 
41.3) 
5  
(3-27.8) 
6.5   
(3-21.75) 
0.55 
EDSS at 2yr  
Median (IQR) 
1  
(1-1.6) 
1  
(0-2) 
1.3  
(1-3) 
1  
(0-1) 
1 (0-2) 0.6 
Follow-up time 
(years) Median 
(IQR) 
3 (2.5-6) 4 (3-
6.75) 
9 (4.75-
13.25) 
3 (2.75-4) 5 (3-8) 0.0143 
^All these 15 cases were AQP4-Ab negative, so 83.3% (15/18) of AQP4-Ab negative patients were 3 
MOG-Ab positive. * This does not include orbital MRI. 4 
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Table 2. Comparison of clinical and paraclinical features in all patients with MOG-Ab-positive 1 
and AQP4-Ab-positive children  2 
 AQP4-Ab  
(n=8) 
MOG-Ab  
(n=26) 
P value  
Demographic characteristics    
Age at presentation median (IQR) 10.5 (6.5-12) 6 (4-8) 0.048 
M: F 1: 7 1: 1.6 0.23 
Ethnicity (white: other) 2: 6 17: 9 0.1 
Demyelinating phenotype at onset    
ADEM 0 (0%) 11 (42.3%) 0.034 
ON 1 (12.5%) 11 (42.3%) 0.21 
TM 3 (37.5%) 2 (7.7%) 0.072 
CIS (other than ON and TM) 4 (50%) 2 (7.7%) 0.018 
First attack symptoms    
Vision  2 (25%) 12 (46.2%) 0.41 
Motor 4 (50%) 7 (26.9%) 0.38 
Sensory/parathesia 2 (25%) 3 (11.5%) 0.57 
Vomiting/nausea/weight loss (AP syndrome) 4 (50%) 1 (3.8%) 0.0067 
Cerebellar symptoms  0(0%) 5 (19.2%) 0.31 
Cranial neuropathies  0 (0%) 3 (11.5%) 1.0 
Seizures  0 (0%) 5 (19.2%) 0.31 
Encephalopathy  2 (25%) 11 (42.3%) 0.44 
ITU admission  2 (25%) 1 (3.8%) 0.13 
Abnormal intracranial MRI at onset 6 (75%) 15 (57.7%) 0.44 
OCB 1/8 (12.5%) 2/22 (9.1%) 1.0 
EBV IgG 0/1 (0%) 7/17 (41.2%) 1.0 
TTFR Median months (IQR) 3 (1.5-4) 9.5 (3.75-24) 0.016 
Demyelinating phenotype at relapse     
MDEM 0 (0%) 9 (34.6%) 0.077 
NMOSD  8 (100%) 15 (57.7%) 0.034 
RON 0 (0%) 2 (7.7%) 1.0 
EDSS at 2-year follow-up  
Median (IQR) 
 
2 (1.25-3.375) 
 
1 (0-2) 
 
0.030 
 3 
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 Table 3. Blinded radiological analysis stratified to antibody positivity.  1 
 2 
 AQP4-Ab 
(n=8) 
MOG-Ab 
(n=26) 
P value 
(AQP4 
vs MOG) 
Both 
antibodies 
negative 
(n=7) 
Not 
tested 
(n=7) 
MRI predominant pattern at onset       
Disease localized to brainstem and 
hypothalamus  
3 
(37.5%) 
0 
(0%) 
0.0094 1 0 
Predominantly confluent, hazy/poorly 
marginated lesions involving both grey and 
white matter 
2 
(25%) 
12 
(46.2%) 
0.422 0 5 
Extensive confluent ‘leukodystrophy-like’ 
pattern 
0 2 
(7.7%) 
1.0 0 0 
LETM and/or ON with normal intracranial 
appearance or non-specific white matter 
lesions 
3 
(37.5%, AP 
involved in 2) 
12 
(46.2%) 
1.0 6 2 
Sharply, demarcated, hemispheric white 
matter lesions (>3cm) 
0 0 1.0 0 0 
Lesion location at onset      
Diencephalon 3 4 0.315 1 1 
Dorsal brainstem 5 3 0.0085 1 1 
Periependymal area 0 0 1.0 1 0 
LETM 5 4* 0.165 3 1 
Cortical grey matter 0 4 0.55 0 2 
Thalamus  0 8 0.152 1 2 
Basal ganglia  0 2 1.0 1 0 
Juxtacortical and deep white mater 
involvement more than periventricular  
0 4 0.55 1 3 
Cerebellar peduncles 0 8 0.030 0 0 
Pons  0 2 1.0 0 0 
Optic nerve/tracts  1 9 0.39 3 0 
MRI predominant pattern at follow-up      
Disease localized to brainstem and 
hypothalamus  
4 0 0.0015 0 1 
Predominantly confluent, hazy/poorly 
marginated lesions involving both grey and 
white matter 
4 11 1.0 1 5 
Extensive confluent ‘leukodystrophy-like’ 
pattern 
0 6 0.30 0 1 
LETM and/or ON with normal intracranial 
appearance or non-specific white matter 
lesions 
0 9 0.077 4 0 
Sharply demarcated hemispheric white 
matter lesions (>3cm) 
0 0 1.0 2 0 
Significant resolution  2 10 0.68 1 4 
Destructive lesions  5 0 0.002 2 0 
Lesion location at follow-up      
Diencephalon 4 2 0.018 1 1 
Dorsal brainstem 7 3 0.0002 1 1 
Periependymal area 2 0 0.05 1 0 
LETM 7 6* 0.033 3 2 
Cortical grey  0 7 0.16 2 4 
  16 
Thalamus  0 10 0.072 0 2 
Basal ganglia  1 2 1.0 1 1 
Juxtacortical and deep white mater 
involvement more than periventricular  
0 5 0.31 0 4 
Cerebellar peduncles 0 14 0.011 0 3 
Pons  0 3 1.0 0 0 
Optic nerve/tracts  1 9 0.38 1 0 
* One child had central cord short transverse myelitis.   1 
 2 
 3 
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 1 
Legends: 2 
Figure 1: MRI patterns observed in MOG-Ab-positive patients: (A)  Deep grey matter disease with 3 
linear pattern of external/extreme capsule disease; (B-C) Significant cortical grey matter involvement; 4 
(D) poorly marginated lesions with involvement of the dorsal brainstem and spinal cord. (E-F) Cerebellar 5 
peduncles & pons: confluent, poorly marginated, mostly reversible lesions; (G-I) Extensive confluent 6 
‘leukodystrophy-like’ lesions. 7 
 8 
Figure 2: Diagnostic algorithm that can be applied to any episode of CNS demyelination in 9 
children. The first recommended diagnostic test is brain and spinal cord MRI. If MRI findings are 10 
considered to be typical or suggestive of adult MS, then the McDonald diagnostic criteria should be 11 
applied. In children whose MRI is not typical or suggestive of MS, but have clinical and radiological 12 
features suggestive of NMOSD, AQP4-Ab testing is recommended. In particular, this test is advised in 13 
children presenting with an area postrema syndrome, MRI abnormalities localised to the brainstem and 14 
hypothalamus, and destructive lesions. If AQP4-Ab are negative, then MOG-Ab should be tested. In 15 
children whose MRI is not typical of MS or NMOSD, but the clinical and radiological presentation has 16 
features of ADEM, MOG-Ab testing is recommended. Supporting features for MOG-Ab associated 17 
disease include lesions in the cerebellar peduncle, and leukodystrophy-like MRI pattern in the very 18 
young. Alternative diagnoses should be considered in the remaining antibody negative patients.  19 
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